Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 25, 2009

Clinical Reference Sets Up U.K. Lab along with Quotient Bioresearch

  • Clinical Reference Laboratory is to establish a European hub in the U.K. as part of a deal with Quotient Bioresearch through which the companies will jointly offer clinical laboratory and other specialist testing services to the global pharma, biopharma, and CRO industries.

    CRL’s new European laboratory will be set up within Quotient Bioresearch’s existing facilities. The companies’ agreement will involve close collaboration to develop new services in areas like bioanalysis, biomarkers, and microbiology.

    “The established capabilities of the two companies are entirely complementary,” comments David Griffiths Ph.D., Quotient’s business development director. “I anticipate synergies that will enable us to deliver a joint offering significantly broader than is available from each party working alone.”

    Quotient specializes in early-stage drug development services and operates three business units: Quotient Radiochemistry and Metabolism, Quotient Bioanalytical Sciences (which includes microbiology), and Quotient Clinical.  CRL offers testing services in the areas of clinical trials, corporate wellness programs, genomics, insurance, and toxicology.


Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »